source
- Kodiak Sciences' Zenkuda shows non-inferior six-month dosing vs Eylea, shares doubleFour years ago Kodiak Sciences saw its share price plunge about 80% after its lead eye-disease candidate failed a head-to-head trial against Regeneron's Eylea, wiping out roughly $2 billion in mark…
- Xaira Therapeutics details its generative AI antibody platform X-Design and unveils first pipeline candidatesXaira Therapeutics, which raised $1 billion in 2024, has now shared details of its AI-driven antibody design platform called X-Design and provided a glimpse of its emerging pipeline. The company s…